Spero Therapeutics, Inc. (NASDAQ:SPRO) Expected to Announce Quarterly Sales of $2.85 Million

Wall Street brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPROGet Rating) to report $2.85 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Spero Therapeutics’ earnings, with the lowest sales estimate coming in at $2.70 million and the highest estimate coming in at $3.00 million. Spero Therapeutics posted sales of $7.30 million during the same quarter last year, which suggests a negative year over year growth rate of 61%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Spero Therapeutics will report full-year sales of $18.49 million for the current year, with estimates ranging from $17.80 million to $19.17 million. For the next fiscal year, analysts expect that the firm will report sales of $110.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPROGet Rating) last released its quarterly earnings data on Thursday, March 31st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.09). Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same period in the prior year, the firm earned ($0.68) earnings per share.

SPRO has been the topic of several analyst reports. HC Wainwright lowered their price objective on Spero Therapeutics from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Monday. Zacks Investment Research cut Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 5th.

SPRO stock traded up $0.27 during midday trading on Friday, hitting $5.96. The company’s stock had a trading volume of 4,697 shares, compared to its average volume of 198,929. The company has a market cap of $195.23 million, a PE ratio of -1.97 and a beta of 1.65. Spero Therapeutics has a 12 month low of $5.55 and a 12 month high of $19.87. The firm’s 50-day moving average is $8.38 and its 200-day moving average is $12.51.

In other Spero Therapeutics news, major shareholder Aquilo Capital Management, Llc purchased 125,000 shares of the business’s stock in a transaction on Monday, January 31st. The stock was acquired at an average price of $11.59 per share, for a total transaction of $1,448,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders bought a total of 176,599 shares of company stock valued at $1,905,663 over the last 90 days. 13.45% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of SPRO. Marshall Wace LLP purchased a new stake in Spero Therapeutics in the 1st quarter worth $39,000. Patriot Financial Group Insurance Agency LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter valued at about $66,000. BNP Paribas Arbitrage SA grew its position in shares of Spero Therapeutics by 358.6% during the third quarter. BNP Paribas Arbitrage SA now owns 4,343 shares of the company’s stock valued at $80,000 after purchasing an additional 3,396 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter valued at about $163,000. Finally, Barclays PLC grew its position in shares of Spero Therapeutics by 79.1% during the third quarter. Barclays PLC now owns 9,965 shares of the company’s stock valued at $183,000 after purchasing an additional 4,401 shares in the last quarter. Institutional investors and hedge funds own 59.17% of the company’s stock.

Spero Therapeutics Company Profile (Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Further Reading

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.